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ABSTRACT 
 
 
Suppression of Manganese-Dependent Production of Nitric Oxide in Astrocytes: 
Implications for Therapeutic Modulation of Glial-Derived Inflammatory Mediators. 
(December 2006) 
Tyler T Wright, B.S., Brigham Young University 
 
Co-Chairs of Advisory Committee: Dr. Ronald B. Tjalkens  
                                                  Dr. Mark J. Zoran 
 
Primary cultured astrocytes were treated with Mn in the absence and presence of pro-
inflammatory cytokines to determine their effect upon stimulation of nitric oxide (NO) 
production. Treatments of manganese and cytokines raised NO production to intermediate 
levels, whereas combined treatment raised NO creation to much greater levels. Furthermore, 
this combined treatment differed from control only in its ability to elevate cellular NO levels 
at 24 hours, but not at earlier time points. Combined exposure in astrocytes derived from 
mice lacking the nos2 gene prevented any increase in production of NO. Thus, manganese 
and cytokines enhance NO production through activation of the nos2 gene. Additionally, 
pharmacologic ligands of the peroxisome proliferator-activated receptor gamma (PPARγ) 
were used to test the role of this orphan nuclear receptor in modulating Mn-dependent 
production of NO. The agonist, 1,1-Bis(3’-indolyl)-1-(p-trifluormethylphenyl) methane 
(cDIM1) diminished NO in a dose-dependent manner, whereas addition of the PPARγ 
antagonist, GW 9662, amplified cellular NO production, also in a dose-dependent fashion. 
Moreover, it was observed that NO production was both attenuated and augmented at similar 
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rates, suggesting the agonist and antagonist work through similar mechanisms. To clarify the 
means by which NO levels are manipulated by PPARγ, we measured activation levels of the 
transcription factor NF-κB, a primary factor resulting in expression of NOS2. We found that 
NF-κB was slightly activated in cells treated solely with manganese or cytokines, whereas 
cells treated with both manganese and cytokines showed the highest levels of activation. 
Also, we found that these ligands function through an NF-κB dependent mechanism. 
Treatment of cDIM1 to astrocytes already treated with manganese and cytokines caused 
decreased activation of NF-κB, while addition of GW9662 to similarly treated cells resulted 
in increased activation of NF-κB.  While these compounds were effective at manipulating 
induction of the nos2 gene, they had no effect on induction of guanosine tri-phosphate 
cyclohydrolase (GTPCH) the rate limiting enzyme for the production of tetrahydrobiopterin 
(BH4), a cofactor essential to the conversion of arginine to NO, Thus, these novel PPARγ 
ligands can influence manganese- and cytokine-induced production of NO by an NF-κB 
dependent mechanism. 
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INTRODUCTION 
Neurodegenerative diseases are a class of disorders that affect brain function by 
the deterioration of necessary neuronal pathways. They are divided into two groups: 
conditions which affect locomotion and those that affect memory and are associated with 
conditions of dementia. These diseases include, but are not limited to, Amylotropic 
Lateral Sclerosis, Multiple Sclerosis, Huntington’s Diesase, and Parkinson’s Disease. 
Parkinson’s disease (PD) is one of the leading causes of death by 
neurodegenerative diseases. Statistics have shown that it affects 1 in 625 people, with a 
mean age of 55 years, indicating increased risk in the elderly population 
(www.cdc.gov/nchs/data/factsheets/Parkinsons.pdf). Clinical cases usually number about 
200 in 100,000 though approximately 2% of the population suffers from it at any given 
time (http://www.pdf.org/AboutPD/). It was first characterized by James Parkinson in 
1817 who documented its symptoms, though the associated neuropathologies were not 
discovered until the 1960’s. PD is part of a larger family of similar diseases known as 
parkinsonism. 
The exact etiology of PD is not clear, though symptoms result from the 
destruction of dopaminergic neurons of the substantia nigra pars compacta. Lewy bodies, 
aggregations of the protein α-synuclein, are generally present, though their role is not 
well understood.  Additional pathologies include neurofibrillary tangles (usually of the 
cerebral cortex) and increased activation of microglia. Symptoms vary among patients,  
________________ 
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but generally fall into two categories: those of a physical nature such as rigidity,  
problems with balance, and akinesia (lack of movement) and those of a psychological 
nature such as depression, dementia, and memory loss.  
Several genetic abnormalities have been identified, each contributing to the 
disease’s onset, though interplay among them isn’t yet well understood. Current theories 
suggest genetic factors confer a vulnerability that can then be exploited by 
environmental toxins, including pesticides and metals. Among the more studied toxic 
agents are 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP), paraquat, and rotenone 
(Kurkowska-Jastrzebska et al., 1999). The substances are commonly used models 
because they quickly induce symptoms seen in PD. 
Much of our current knowledge of parkinsonism results from research using 
MPTP. The compound was first discovered when a group of drug addicts injected a 
batch of MPTP-tainted heroine. The addicts developed symptoms similar to those in 
seen in parkinsonism patients (Langston et al., 1983). It was later discovered that MPTP 
injection into rodents and primates recapitulated many of the neurologic and 
neuropathologic features of PD in humans, leading the hypothesis that environmental 
agents may play an important role in the disease process.   
Manganese  
Manganese is a divalent transition metal similar to iron in that it can be either 
necessary for vital function or toxic to it depending on the concentration ingested. Levels 
of manganese are not controlled by its sequestration, but rather through regulation of its 
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reabsorption and secretion, as well as by the blood brain barrier (Aschner and Aschner, 
1991). Its removal from the brain is very slow (Dastur et al., 1971). 
Manganese poisoning may occur in both industry and agriculture (Rodier, 1955). 
The resulting disorder, termed manganism, is characterized by neurologic symptoms 
resembling PD, including dystonia as a result of loss of striatal dopamine. While 
symptomatic similarities exist between parkinsonism and manganism, there are major 
differences both histological and physiological (Calne et al., 1994). Literature suggests 
that manganese wields toxic effects on mitochondrial function and Ca2+ homeostasis.  
After manganese is administered in vivo, it accumulates within nuclei of the 
basal ganglia, including the globus pallidus, striatum, and substantia nigra pars reticulata 
(Yamada et al., 1986). Mitochondrial dysfunction is central to the neurotoxicity of Mn. 
Underlying this effect is the known capacity of Mn to affect mitochondrial calcium 
dynamics (Liu et al., 2006). Both calcium and manganese are taken into the mitchondria 
by the uniporter Ca2+ pump at normal physiological levels, but excessive Mn2+ will 
inhibit Na+-dependent efflux of calcium, resulting in increased levels of matrix calcium 
(Konji et al., 1985). Manganese binds tightly to the inner mitochondrial membrane, 
where it is oxidized to M3+, a species thought to inhibit oxidative phosphorylation 
(Gunter and Puskin, 1975).  Overaccumulation of Mn2+ can interfere with oxidative 
phosphorylation by replacing Mg2+ or Ca2+ at binding sites of enzymes (Gunter and 
Pfeiffer, 1990). Astrocytes are able to avoid negative consequences by rerouting 
principal ATP production through glycolysis (Almeida et al., 2001). While Na+- 
dependent efflux of Ca2+ is much faster than the Na+-independent mechanism, Mn2+ 
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clearance does not happen in this manner. The amassing of Mn2+ in mitochondria aids in 
explaining its accumulation in the brain. Studies suggest that more Mn2+ promotes Ca2+ 
overload within the mitochondria, thereby enhancing neuronal apoptosis (Liu et al., 
2005). 
The pathophysiology of parkinsonism points to destruction of neurons in the 
substantia nigra pars compacta of the basal ganglia. The basal ganglia is a group of 
neurons whose primary responsibility is the partial regulation of voluntary movement. 
Even though there exists no direct connection with the spinal cord, the basal ganglia 
exerts its effects by receiving its input from the cerebral cortex and relaying information 
back to the cortex through the thalamus and brainstem. It consists of four nuclei, the 
striatum, the globus pallidus (pallidum), the substantia nigra, and the subthalamic 
nucleus. The striatum receives input from the cortex and then projects to the substantia 
nigra and the globus pallidus, which contains an inner and an outer segment. Together 
with the subthalamic nucleus, the inner pallidum comprises the output nuclei, which 
projects to both the thalamus and the brain stem (Albin et al., 1989). 
The cortex sends excitatory glutamatergic signals to the striatum, which in turn 
relays it to other areas of basal ganglia. The vast majority of these cells are GABA-ergic 
and inhibitory by nature, including the two output nuclei which send constant inhibition 
to their targets in the brainstem and thalamus. There are two pathways that control this 
inhibition, the direct pathway and indirect pathway. The direct pathway travels from the 
putamen of the striatum to the inner pallidum and then onto output nuclei. Since these 
neurons are GABA-ergic, activation of the direct pathway inhibits the pallidal regions 
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which allows for the “de-repression” of neurons in the thalamus and brainstem, and 
thereby increases motor activity. The indirect pathway passes from the putamen to the 
external globus pallidus and then onto subthalamic nucleus before re-joining the direct 
pathway at the internal globus pallidus. Because the connection between the subthalamic 
nucleus and the internal pallidum is glutamatergic, activation of this pathway will 
increase the inhibition of the internal pallidum, which will then yield greater motor 
activity through the decreased inhibition of the thalamus and brain stem (Hoover and 
Strick, 1993). Dopamine is the neurotransmitter that activates both the indirect and direct 
pathways. Though they receive the same stimulus from the substantia nigra pars 
compacta, the pathways are able to exert differing effects because the dopamine is 
received by separate receptors, D1 to initiate the direct pathway and D2 receptors to 
initiate the indirect pathway (Gerfen et al., 1995).  
Symptoms of Parkinson’s disease stem from depletion of dopamine in the striatum, 
which results from degeneration of dopaminergic neurons in the substantia nigra pars 
compacta. With dopamine unavailable, neither the direct nor indirect pathway can be 
stimulated and tonic inhibition of the thalamus and brainstem cannot take place, 
resulting in extraneous movement characteristic of the disease. Dopamine mimetics have 
proven successful in reducing symptoms, but effects are not permanent (Albin et al., 
1995).  
Manganism vs. Parkinsonism 
Principal pathologies resulting from manganism include neuronal degeneration 
and glial activation.  Neuronal destruction occurs principally in the globus pallidus and 
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the substantia nigra pars reticulata, whereas neuronal degeneration characteristic of  
parkinsonism usually occurs in the substantia nigra pars compacta (Yamada et al., 1986). 
Reactive astrogliosis is also a key feature (Bikashvili et al., 2001). As stated previously, 
neuronal degeneration of the pre-nigrostriatal neurons is seen in parkinsonism. However, 
it is post-synaptic destruction that is more common in manganese poisoning (Kessler et 
al., 2003).  
Such neuronal destruction increases the cytoplasmic levels of Ca2+ to potentially 
toxic planes (Gavin et al., 1990). Increased matrix calcium leads to amplified levels of 
oxygen radicals, including Reactive Oxygen Species (ROS) (Kowaltowski et al., 1995). 
Mitochondrial dysfunction may then affect several downstream factors leading to 
transcription of pro-inflammatory genes, including inducible Nitric Oxide Synthase 
(iNOS). Increased manganese concentrations eventually lead to increased activation of  
NF-κB through the NIK pathway which leads to phosphorylation and activation of NF-
κB (Barhoumi et al., 2004). 
Nitric Oxide and the Inflammatory Response 
Microglia are a type of glial cell discovered by del Rio-Hortega, a student of 
Ramon Y Cajal. They have many functions, including the regulation of neuronal 
differentiation and apoptosis. It has also been postulated that microglia can aid the 
growth and division of oligodentrocytes and astrocyes through the production of 
cytokines. Their primary function, however, is inflammatory. When brain injury occurs, 
microglia actually transform into cells with smaller processes and larger cell bodies. 
These microglia are then known as “activated” or “reactive” (Bikashvili et al., 2001). It 
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is important to distinguish between a single transient microglial response due to isolated 
occurrences and continual activation as it occurs during a disease state, such as 
Parkinson’s Disease. Other studies indicate that neuronal cell loss is due to increased 
Reactive Oxygen Species (ROS). When compared to most other brain regions, the 
substantia nigra is replete with microglia (Kim et al., 2000b). Microglia are the principle 
immunological component of the nervous system. They are very reactive and take action 
quickly and continuously to injury within the central nervous system. Once the microglia 
sense damage, they respond to the site of injury and proliferate there (Stefano et al., 
2004). 
Production of NO from arginine in the body is catalyzed by a group of enzymes 
known as nitric oxide synthase(s). There exist three principle different subtypes which 
share approximately 50-60% homology (Masters et al., 1996). They are eNOS 
(endothelial NOS, also called NOS1), iNOS (inducible NOS, also called NOS2) and 
nNOS (neuronal NOS, also called NOS3).  NOS1 and NOS3 are consititutive, and are 
activated by the presence of calcium and calmodulin. Upon an activation signal, NO is 
synthesized in very low concentrations by NOS1 and NOS3 and activates the second 
messenger cyclic GMP, which will then regulate a series of other signals. NOS2 is not 
present in resting cells, but rather is “turned on” by an immune signal, including 
infection in a number of cells like endothelium, monocytes, macrophages, and 
astrocytes. In contrast to the other two isoforms, it is independent of intracellular 
calcium levels (Xie et al., 1993). NOS exists in dimer form and this configuration is 
stabilized by the presence of the necessary co-factor tetrahydrabiopterin (BH4) (Tzeng et 
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al., 1995). Outside of its function in NOS stability, it is also thought to aid NOS mRNA 
stability (Stuehr, 1997). Its availability is rate limiting in NOS synthesis (Kidd et al., 
2005). 
NF-κB   
NF-κB  is a cytokine-inducible transcription factor key to the inflammatory 
response. It is made up of various complexes of the Rel family of proteins, which 
include p65 (RelA), RelB, c-Rel, p50, and p52. Common among them is a 300 residue 
domain (termed Rel homology domain) that is important for both dimerization and DNA 
binding. The NF-κB family of proteins exists in the cytoplasm in various combinations 
and remains there until activation. A myriad of factors, both environmental and 
endogenous, can  trigger the NF-κB signaling pathway, which eventually results in the 
activation of inducible nitric oxide synthase (iNOS). Activation results from 
phosphorylation of two serine residues (Ser 32 and 36) of the inhibitory sub-unit, IκB. 
Its phosphorylation leads to its subsequent ubiquitination and degredation by the 26S 
proteasome. Ubiquitination of IκB must also be specific. In order for IκB to be degraded 
it must be ubiquitinated at Lys 21 and Lys 22. Site specific mutation (lysine to arginine) 
leads to a protein that is phosphorylated but not degraded, and therefore does not 
properly release NF-κB (Rodriguez et al., 1996). 
  NF-κB has many endogenous activators, including the pro-inflammatory 
cytokines. Studies in C6 glioma cells have shown that none of the pro-inflammatory 
cytokines (TNF-α , IL1—β, and IFN-γ) and LPS are unable to induce NF-κB activation  
alone, but only in combination with one another (Pahan et al., 1999; Uehara et al., 1999). 
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There is also a wide range of agents besides those mentioned can induce nuclear 
translocation and activation of NF-κB.  It is of note that many of these inducers of NF-
κB are also inducers of iNOS expression in certain cell types namely the β-amyloid 
protein present in Alzheimer’s disease which has been shown to induce both NF-κB and 
iNOS in the mouse astroglial cell (Heneka et al., 2003).  
TNF-α activates NF-κB by interacting with TNF-α receptor associated factors 
(TRAF) which then in turn activates NF-κB inducing kinase (NIK)(Kim et al., 2005; 
Yang et al., 2005). Other cytokines follow similar pathways. Activated NIK then 
activates the inhibitory κB complex which then phosphorylates serine 32 and 36 of IκB. 
NF-κB is then free to bind DNA (Barhoumi et al., 2004). 
NF-κB dependent gene expression requires several co-transactivators that may 
function by modifying chromatin structure or by otherwise physically assisting 
transcription factor binding. The NF-κB subunit p65 requires the coactivator CBP 
(cyclic AMP response element being protein [CREB]-binding protein) and p300 
(Gerritsen et al., 1997; Perkins et al., 1997). These coactivators are known to mediate 
histone acetyl-transferase (HAT) activity. HAT proteins place acetyl groups on the 
histones, thereby causing dissociation from the chromatin and allowing transcription to 
occur. Conversely, repressors often work through association with histone deacetylases 
(HDACs). As their name implies, they act through deactylation of histones and 
subsequent reassociation of histones with associated DNA sequences. N-CoR (nuclear 
receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) 
are corepressors that act in the manner described above, in that they partner with HDACs 
                                                                  
  
 
10
(specifically HDAC3) to repress transcription. They are known to do this by binding 
with a number of nuclear receptors and physically impeding transcription (Chen and 
Evans, 1995; Horlein et al., 1995; Glass and Rosenfeld, 2000; Guenther et al., 2000; Li 
et al., 2000; Zhang et al., 2002; Yoon et al., 2003). Interestingly, recent studies have 
shown that N-CoR and SMRT are also necessary for repression of NF-κB activated 
genes, including nos2 (Hoberg et al., 2004; Ogawa et al., 2004; Perissi et al., 2004).  
 The subunit p65 contains at least five serines that are phosphorylated at various 
times, though the functions of all phosphorylation events are not completely clear. 
However, it is likely that phosphorylation of serine 276 is necessary for coactivation 
(Okazaki et al., 2003). Similar to p65, the p50 subunit also requires coactivating factors. 
Both steroid receptor-coactivator-1 (SRC-1) and nuclear receptor coactivator-1 (NCoA-
1) are necessary to insure proper DNA binding (Heery et al., 1997; Torchia et al., 1997; 
McInerney et al., 1998). 
Earlier studies identified NF-κB as an important transcription factor in the LPS-
induced expression of iNOS in the murine RAW 264.7 macrophage cell line. Deletional 
analysis of iNOS showed locations of NF-κB binding sites. Mutation of these sites 
exposed an inability of the transcription factor to bind and commence expression of the 
reporter gene (Kim et al., 1997).  
Important differences have been identified in the regulation of iNOS expression 
in different cell types. For instance, in mouse macrophages, the downstream NF-κB site 
between -85 to -76 is apparently more important than the upstream NF-κB site at -971 to 
-962 for LPS inducibility. However, in  TNF-α , IL1-β, and IFN-γ-stimulated vascular 
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smooth muscle, the upstream NF-κB  site at -971 to -962 is more functional. 
Furthermore, both LPS induction and the synergistic response to LPS plus IFN-γ were 
mapped to an upstream enhancer DNA sequence that included the upstream NF-κB  site 
at -971 to -962. Both the upstream and the downstream NF-κB sequence elements have 
been shown to bind various NF-κB family members in different cell types and in 
response to differing stimuli. Studies reveal that particular NF-κB  proteins bind to 
different NF-κB sequences with distinct affinities in a cell type and stimulus dependent 
fashion (Lowenstein et al., 1993; Alley et al., 1995). The complete mechanism is not yet 
understood. 
 Gavrilyuk and colleagues show that the presence of the proximal NF-κB binding 
sites is not sufficient to confer induction by LPS and cytokines (Gavrilyuk et al., 2001). 
Instead, upstream activator sequences are needed. There are several response elements 
that appear cooperative in NF-κB binding, some of these include Oct-1 elements, 
interferon response elements, and JAK/STAT binding elements.  
PPARγ 
The peroxisome proliferator activated receptors (PPARs) are a group of nuclear 
receptors with a wide range of functions across cellular and molecular biology. 
Originally named for their ability to proliferate peroxisomes in rodent livers, they have 
been connected to functions as diverse as metabolism, inflammation, and cell 
differentiation. Three different isoforms, PPARα, PPARδ, and PPARγ have been 
identified. Each is transcribed by different genes and therefore has slightly different 
binding domains and binding partners. PPARα is found in the liver, heart and kidney. 
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PPARδ is expressed in most tissues and PPARγ is most commonly found in adipocytes 
and macrophages. The distinct distribution of tissues implies that each isoform has 
unique functions.  
PPARγ is a member of the nuclear receptor family whose activity is regulated by 
direct binding of hormones, vitamins, and various lipid metabolites. Generally, once the 
ligand binds to PPARγ, it then heterodimerizes with Retinoid X Receptor-α (RXRα) 
before translocating to the nucleus and binding to specific DNA sequences known as 
PPAR response elements (PPREs) (Cullingford et al., 1998; Qi et al., 2000). It is through 
this classical pathway that it exerts its effects on adipogenesis and glucose homeostasis 
for which it is most well known. Binding to PPREs is known to induce adipogenesis as 
well as monocyte differentiation (Kim et al., 2000a). PPARγ is composed of several 
functional domains, and contains a highly conserved DNA binding domain and two 
transactivation domains: one transactivation domain, a N-terminal ligand independent 
domain and a C-terminal domain that is very much ligand dependent (Klein et al., 2005). 
This C-terminal domain is responsible for ligand binding, heterodimerization, and 
transactivation. PPRE binding, as is considered a positive regulatory event (Tanaka et 
al., 2005). When united with ligand, the ligand binding domains alter their conformation 
to allow recruitment of coactivators. This recruitment of coactivators depends upon a 
highly conserved motif that changes conformation to become part of the “ligand binding 
pocket” when ligand is attached (Hegele, 2005). While many coactivators have been 
characterized, the most commonly studied for PPARγ activation is SRC-1 which recruits 
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p300 and CREB-binding protein (CBP), though CBP binds directly to PPARγ, in some 
cases without the aid of SRC-1 (Qi et al., 2000).  
Additionally, recent studies show PPARγ to be a major participant in 
inflammatory processes. Both natural and synthetic ligands have been known to exert 
anti-inflammatory effects in experimental cases of encephalomyelitis, rheumatoid 
arthritis, and inflammatory bowel disease (Kawahito et al., 2000; Diab et al., 2002; 
Adachi et al., 2006). Ricote and colleagues demonstrated that PPARγ is a negative 
regulator of inflammation in macrophages by inhibiting induction of iNOS, among other 
genes (Ricote et al., 1998). In contrast to its other functions in which it binds directly 
PPREs, PPARγ influences inflammation by imposing on inflammatory transcription 
factors such as NF-κB, STAT, and AP-1 (Chinetti et al., 1998). 
Evidence has shown 15d-PGJ2 to be an endogenous ligand for PPARγ. Thus it is 
believed that activation of PPARγ by 15d-PGJ2  and other ligands may stimulate release 
of PPARγ from its repressor and therefore allow contact with co-activators and its 
successive nuclear translocation (Ide et al., 2003). It was recently shown that PPARγ 
activated by 15d-PGJ2   competes with p300/CBP for transactivation of the IFN-γ 
promoter, thereby inactivating it (Farrajota et al., 2005). As stated previously, there is 
clear evidence that activation of PPARγ attenuates pro-inflammatory cytokine and iNOS 
expression in astrocytes (though not human brain macrophages) and, by extension, 
lowers nitrite production. Such anti-inflammatory effects are activated by structurally 
distinct ligands that include non-steroidal, anti-inflammatory drugs (NSAIDS), 
thiazolidinediones, and the aforementioned 15d-PGJ2 (Consoli and Devangelio, 2005; 
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Townsend and Pratico, 2005; Zhao et al., 2006). Research shows that 15d-PGJ2  inhibits 
NF-κB at multiple locations, both diminishing its capacity to bind DNA and hindering 
its ability to migrate to the nucleus by inhibiting phorphorylation of IKK (Zhao et al., 
2004).  
A great deal of recent research has focused on the thiazolidinediones. This class 
of PPARγ ligands, which includes troglitizone, rosiglitizone, and ciglizitone, is most 
well known for its anti-diabetic effects. Further investigation has shown clinical utility in 
other areas as well, including inflammation (Consoli and Devangelio, 2005). Recent 
evidence has shown that this class of pharmacological agents has diminishing effects on 
BH4 synthesis by inhibiting its rate limiting enzyme, guanonsine triphosphage 
cyclohydrolase (GTPCH) (Linscheid et al., 2003). 
Recently, the mechanism PPARγ mediated inhibition of the NF-κB pathway has 
been established. Activation and nuclear transclocation of  PPARγ leads to its 
association with complexes of NCoR and HDAC3 that are present near the promoters of 
inflammatory genes, such as nos2. Such association does not allow recruitment of 
necessary cofactors that are accountable for the elimination of the NCoR repressor and it 
remains bound to the promoter, disallowing transcription (Pascual et al., 2005). 
A new class of PPARγ agonists has been characterized. 1,1-Bis (3’indolyl)-1-(p-
substitutedphenyl methanes) also called diindolylmethanes or DIMs have shown efficacy 
in retarding growth within breast, colon, and pancreatic cancer cell lines by activation of 
PPARγ. It has been associated with cell division associated pathways, including 
inhibition of the G0/G1 –S phase the cell cycle (Chintharlapalli et al., 2004; Hong et al., 
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2004; Qin et al., 2004). To date, however, these compounds have not been tested for 
their efficacy in anti-inflammatory capacities. We will attempt to answer this question by 
first establishing a relationship between these ligands and affected levels of produced 
NO. We will then seek to establish the mechanism of action of these ligands in part, by 
determining their relationship with NF-κB. We will further seek to determine the 
mechanism of this interaction by testing these agent’s abilities to diminish NO synthesis 
by inhibiting production of BH4’s rate limiting enzyme, GTPCH. 
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MATERIALS AND METHODS 
 
 
 
Cell Culture 
 Primary cortical astrocytes were isolated from neonatal mice pups and plated on 
60 mm plates obtained from VWR (West Chester, PA). Cells were incubated in CO2 
tanks in Minumum Essential Media obtained from Invitrogen, with 10% Fetal Bovine 
Serum and a combination of Penicillin, Streptomycin, and Neomycin, all obtained from 
VWR. Mice containing a nos2 knockout were obtained from The Jackson Laboratory 
(Bar Harbor, ME) and were cultured in identical manner. 
Fluorescence Microscopy 
 Nitric Oxide was measured using the fluorescent marker, 4-amino-5-
methylamino -2’,7’-difluoroflorescein diacetate (DAF-FM)  obtained from Molecular 
Probes (Carlsbad, CA), prepared as a 5mM stock solution in DMSO and diluted in 
culture media to a final concentration of 5µM for imaging studies. For analysis of nitric 
oxide production in astrocytes, including both wildtype and astrocytes in which the nos2 
gene has been excised, the fluorescence emission intensity of DAF-FM was determined 
kinetically by collecting images at 488nmEX/515nmEX emission at five minute intervals 
for 55 minutes at exposure times of 20 milliseconds in order to allow the reaction of NO 
with DAF-FM to reach equilibrium. After incubation with various treatment media, cells 
were treated and incubated with DAF-FM for a period of ten minutes. Intensity data 
were then analyzed by calculating a normalized fluorescence value for each image as 
df/F0, where df represents the background-subtracted fluorescence of a given cell at time 
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(t) divided by the fluorescence of the same cell at time zero. Analysis was performed 
using Slidebook, v. 4.1; Intelligent Imaging Innovations, Inc. (Denver, CO). Data were 
further analyzed by averaging the maximum intensities and comparing to maximum 
averaged control values, and displayed as fold difference. Furthermore, sequential 
fluorescence time points for each image, again calculated as df/F0, were displayed as line 
graphs.  
NF-κB Activation 
 To determine the amount of NF-κB activation elicited, we obtained a transgenic 
mouse from the laboratory of Dr. David Brenner that contained astrocytes in which a 
novel enhanced green fluorescent protein (EGFP) reporter had been placed. This reporter 
gene is under the control of NF-κB and fluoresces as NF-κB is activated and induces 
transcription. Qualitative images were taken in the presence of  manganese, cytokines, 
and PPARγ ligands to determine their role in NF-κB activation. These cells were 
cultured in the manner described above. 
Real-Time 
 
 Astrocytes were isolated from mice. RNA was isolated from astrocytes plated on 
60 mm tissue culture plates from VWR (West Chester, PA) using the RNeasy Mini Kit 
from Qiagen (Valencia, CA) . Previous to isolation, astrocytes were treated for 24 hours 
with combinations of 50 µM MnCl2, pro-inflammatory cytokines Tumor Necrosis 
Factor-α (TNF-α) and Interferon-γ (IFN-γ), as well as varying concentrations of the 
peroxisome proliferator activated receptor-γ (PPAR-γ) agonist  1,1-Bis (3’-indolyl)-1-(p-
trifluormethylphenyl) methane (cDIM1) and antagonist GW 09266. After isolation, 
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RNA was quantified using a Beckman-Coulter Spectrophotometer. The reverse 
transcription was carried out with 1µg of RNA, 1 µL of dNTPS and 1 µL of oligo DTs, 
both from Bio-Rad (Hercules, CA). Mixtures were then incubated at 65°C for five 
minutes, before being briefly chilled on ice. A second mix was created using 5X 1st 
strand buffer, .1 DTT, RNase Out RNase inhibitor, and Superscipt III Reverse 
Trancscriptase. Mixes were combined for each treatment and then incubated at 42°C for 
50 minutes, then incubated at 70°C for 15 minutes. 
 Upon removal from the incubation, samples were brought up to 50 µL with 
DNase/RNase free water from Qiagen. 5 µL of sample was added to 20 µL of supermix 
which included 12.5 µL Bio-Rad’s Sybr Green, 1.25 µL of both sense and anti-sense 
primers, and 5 µL of RNase/DNase free water. Primers were designed using the Beacon 
designer program. Samples were then spun down and briefly placed on ice. The plate 
was then loaded into Biorad’s I-cycler. Samples were incubated in the I-cycler at 95°C 
for 3 minutes and 30 seconds, followed by alternating incubations of 10 seconds at 95°C 
and 1 minute at 55°C. They were then incubated at 55°C for 80 cycles of 1 minute. Melt 
Curves were also run to determine purity. Data was analyzed using the 2-∆∆CT method 
outlined by Livak and Scmittgen (Livak and Schmittgen, 2001). 
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RESULTS 
 
Nitric Oxide Production in Primary Astrocytes 
 We investigated whether manganese, together with cytokine activation of 
inflammation regulatory pathways, induces nitric oxide synthase (nos2) activity in 
mouse astrocytes. Nitric oxide synthase activity in primary cultures of astrocytes was 
estimated using an NO production indicator, difluoroflorescein diacetate (DAF-FM), and 
fluorescence microscopy (Figure 1). Manganese treatment of primary astrocytes 
increased nitric oxide production in a time-dependent fashion. Exposure of astrocytes to 
50µM MnCl2 and the pro-inflammatory cytokines 1µg/ml TNF-α and 10 ng/ml INF-γ 
did not significantly increase nitric oxide production at 0, 4, and 8 hours over saline 
control, but did increase nitric oxide production by 25% over controls following a 24h 
treatment (Figure 2). Based on these results, astrocytes were treated with either 
manganese or the aforementioned cytokines for 24h in all subsequent experiments. 
Addition of either MnCl2 alone or the two cytokines in concert increased nitric oxide 
production 15 and 18%, respectively (Figure 3). Again, in these experiments, exposure 
to manganese and cytokines together elicited a synergistic increase in NO production 
greater than 35% (Figure 3).  
 Identical DAF-FM measurements were conducted in primary astrocytes cultured 
from knock out mice in which the inducible nitric oxide synthase gene (nos2) was 
deleted. In these nos2 null astrocytes, treatment with manganese and cytokines, both 
separately and together, had no effect on nitric oxide production (Figure 4). Thus, the   
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Figure 1 Synergistic enhancement of manganese and cytokines on nitric oxide production.  
Representative psuedocolored images of primary cultures of astrocytes. Astrocytes were 
treated with manganese, cytokines, and a combination of the two. Cells were visualized by 
fluorescence microscopy using cell permeant NO dye DAF-FM. The color bar represents 
differing levels of NO produced. 
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Mn and I/T Treated            
 
Control                               
Figure 2 Time dependent production of nitric oxide in primary astrocytes. Cells were 
visualized by fluorescence microscopy using cell permeant NO dye DAF-FM. Bars 
represent percentage difference from control at 0 hrs (mean ± SEM of data compiled 
from 2 experiments; n=439).  Significant difference (p<0.05) is indicated by different 
letters. Line graphs represent increase in df/Fo. 
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Figure 3 Synergistic enhancement of manganese and cytokines on nitric oxide production. 
NO production was measured by fluorescence imaging primary astrocyte cultures. Cells 
were visualized by fluorescence microscopy using cell permeant NO dye DAF-FM.  Bars 
represent percentage difference from control (mean ± SEM of data compiled from 3 
experiments; n=368). Significant difference (p<0.05) is indicated by different letters.  Line 
graphs represent increase in df/Fo.  
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Figure 4  NO production in the presence of manganese and cytokines in nos2    
       knockout astrocytes (mean ± SEM of data compiled from 3 experiments;  
       n=146). Cells were treated with manganese and cytokines. NO production    
       was measured by fluorescence imaging primary astrocyte cultures using the  
       cell permeant NO dye DAF-FM. Bar graphs represent increase in df/Fo.  
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increases in NO production, as well as well as their synergistic effects, are entirely due 
to  the induction of nos2. 
To investigate the role of peroxisome proliferator activated receptor-γ 
Mn/cytokine induction of nos2 activity, we used pharmacological manipulation to 
enhance or suppress PPARγ activity. The PPARγ antagonist GW9662 was added to 
astrocyte cultures as DAF-FM measurements of NO production were performed (Figure 
5a). Treatment with both manganese and cytokines, in the presence of increasing 
concentrations of GW9662, caused a dose-dependent increase in NO production (Figure 
5b). Addition of 0.1 µM GW9662 induced an increase of approximately 10%, in 
comparison to treatment with Mn/cytokines alone. Following a 10 µM GW9662 
treatment, a greater than 35% enhancement of nos2 activity, as determined by nitric 
oxide production, was measured. The PPARγ agonist cDIM1 attenuated NO production 
in primary astrocytes in a dose-dependent fashion (Figure 6). Addition of the agonist at 
0.01 µM and 1 µM significantly decreased NO production by approximately 20% and 
28%, respectively. Thus, in primary astrocyte cultures, agonist-mediated activation of 
PPARγ suppressed nos2 activity; whereas, antagonists of PPARγ enhanced NO 
production in these glial cells. evels over the hour time course of the DAF-mediated NO 
measurement following treatment 
 In the hour following 24h of exposure to either MnCl2 alone or the two cytokines 
without MnCl2, NO increased steadily to its max value with both manganese and  
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Figure 5 Effect of PPARγ antagonist GW 9662 on manganese- and cytokine- derived 
nitric oxide production in primary astrocytes.  Cells were visualized by fluorescence 
microscopy using cell permeant NO dye DAF-FM.  a) Representative psuedocolored 
images are shown of astrocytes that have been treated with manganese, cytokines, 
and the antagonist GW9662. b) Bar graphs represent increase in df/Fo (mean ± SEM 
of data compiled from 3 experiments; n=273). Significant difference (p<0.05) is 
indicated by different letters. 
a 
b 
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Figure 6  Effect of PPARγ agonist 1,1-Bis(3’-indolyl)-1-(p-trifluormethylphenyl) methane  
(cDIM1) on manganese- and cytokine-derived nitric oxide production in primary 
astrocytes. NO was visualized by fluorescence microscopy using a the cell permeant NO 
marker, DAF-FM. a) Representative psuedocolored images b) Bars represent percentage 
difference from control (mean ± SEM of data compiled from 3 experiments; n=244). 
Significant difference (p<0.05) is indicated by different letters. 
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cytokines. Addition of the PPARγ ligands, both agonist and antagonist caused a steady 
(though at times erratic) decrease (25%) and increase (28%) respectively over the hour 
of treatment when compared to the astrocytes treated only with manganese and 
cytokines (Figure 7). 
NF-κB Activation in Primary Astrocytes  
Having determined the efficacy of these PPARγ ligands to affect nos2 derived 
NO production, we sought to elucidate the mechanism underlying these changes. As 
stated previously, research has shown that PPARγ exerts it effects on inflammatory 
processes through interaction with NF-κB, a primary inflammatory transcription factor. 
To determine if PPARγ ligands function in an NF-κB-dependent manner, astrocytes with 
an enhanced green fluorescent protein (EGFP) reporter of NF-κB transcriptional 
activation were treated under various conditions and assessed for fluorescent activity 
(Figure 8). Thus, greater fluorescence corresponded to greater transcriptional activation 
by NF-κB. Under identical treatment conditions as described earlier, we added MnCl2 
and TNF-α and INF-γ both separately and in concert. We found that while the additions 
of cytokines and manganese both enhanced fluorescence over control cultures, the 
addition of the two in concert caused activation greater than addition of either by itself 
(Figure 9). Therefore, we see that manganese has an enhancing effect on cytokine-
elevated, NF-κB-dependent transcriptional activation. 
Furthermore, we sought to test the effect of PPARγ ligands on NF-κB-dependent 
transcriptional activation by adding both the PPARγ agonist cDIM1 and the PPARγ  
antagonist GW 9662 to cultured astrocytes treatments. We found that addition of the  
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Figure 7 Time course of nitric oxide production in primary astrocytes treated with cDIM1 and 
GW9622. The control group was treated with manganese and cytokines while the treated group 
received manganese, cytokines, and PPARγ ligands. Lines represent percentage difference from 
manganese and cytokine treated controls over the same hour. (mean ± SEM of data compiled 
from 2 experiments; n=127).   
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+Mn+ I/T 
cDIM1 1.0µM 
+Mn+ I/T Ctrl 
      Mn+ I/T 
GW 1.0µM 
Figure 8 Effect of manganese and cytokines separately and together and with additions of  
cDIM1 and GW 9662 on NF-κB activation in primary astrocytes. Astrocytes contain an EGFP 
reporter that fluoresces green with increased transcriptional activation by NF-κB. 
Representative images are shown. 
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c 
Figure 9 Effect of manganese and pro-inflammatory cytokines on NF-κB activation in primary 
astrocytes. a) Astrocytes contain an EGFP reporter that fluoresces green with increased 
transcriptional activation by NF-κB. b) Bar graphs are measures of fluorescence shown in 
arbitrary units (au), with n=5. Significant difference (p<0.05) is indicated by different letters, as 
shown by a, b, and c. 
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agonist diminished EGFP fluorescence in a dose dependent manner, with addition of 1 
µM agonist causing the greatest degree in fluorescence and additions of 0.1 µM and 0.01 
µM causing subsequently less inhibition (Figure 10). Suprisingly, however, it was noted 
that the greatest activation of EGFP fluorescence by the PPARγ antagonist did not occur 
with the highest concentration (10µM), but rather by addition of 1µM GW 9662. It  
It should be noted that the 10µM treatment did induce activity, but to a lesser 
degree (Figure 11). Statistically, we found that such findings show that not only do these 
PPARγ ligands affect nitric oxide production by altering nos2 activation, they also do so 
by influencing the degree to which NF-κB is activated and therefore manipulate its 
ability bind to the nos2 promoter and activate its transcription. 
Induction of GTPCH and nos2 
 With the understanding that PPARγ-induced alteration of NO production in 
primary astrocytes is NF-κB dependent, we inquired to know whether other mechanisms 
played a role in these variations. Specifically, we examined the effect of PPARγ on 
iNOS’s necessary cofactor, tetrahydrobiopterin by monitoring the expression of its rate 
limiting enzyme, guanosine triphosphate cyclohydrolase (GTPCH). Consistent with our 
previous results, we found that manganese- and cytokine-treated astrocytes increased 
iNOS expression increased significantly, by almost two and half times (Figure 12a). 
Furthermore, GTPCH expression was significantly augmented by the addition of 
manganese and cytokines, specifically an increase of 120%. (Figure 12b). Also 
consistent with our previous findings, cDIM1 decreased iNOS expression by 80% 
(Figure 13a), while addition of GW9662 showed a corresponding increase of almost four  
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Figure 10 Effect of PPARγ agonist cDIM1 on manganese- and cytokine-derived NF-κB activation in 
primary astrocytes. Astrocytes contain an EGFP reporter that fluoresces green with increased 
transcriptional activation by NF-κB.  Bar graphs are measures of fluorescence shown in arbitrary units 
(au), with n=5. Significant difference (p<0.05) is indicated by different letters, as shown by a, b, and c. 
 
cDIM1  (µM) 
50 µM Mn
+TNFα/IFNγ + + + + 
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Figure 11 Effect of PPARγ antagonist GW 9662 on manganese- and cytokine-derived NF-κB activation 
in primary astrocytes. Astrocytes contain an EGFP reporter that fluoresces green with increased 
transcriptional activation by NF-κB. b) Bar graphs are measures of fluorescence shown in arbitrary 
units (au), with n=5. Significant difference (p<0.05) is indicated by different letters, as shown by a and 
b. 
GW 9662 (µM) 
50 µM Mn 
+TNFα/IFNγ 
+ + + + 
a
a
a 
b
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Figure 12 Effect of manganese and cytokines on induction of  iNOS and GTPCH in primary astrocytes. 
a) Treatment effects on iNOS induction. b) Treatment effects  on GTPCH induction. Expression was 
measured by real-time polymerase chain reaction and displayed as a percentage of the control with 
n=3. Significant difference (p<0.05) is indicated by different letters, as shown by a and b. 
Control Mn +I/T
0.0
0.5
1.0
1.5
2.0
2.5
a 
b 
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50µM Mn+ 
TNFα/IFNγ + + 
a
b
b 
50µM Mn+ 
TNFα/IFNγ + + 
a
b
Figure 13 Effect of PPARγ ligands on iNOS induction in primary astrocytes. a) iNOS 
induction in the presence of cDIM1. b) iNOS induction in the presence of GW 9662. 
Expression was measured by real-time polymerase chain reaction and displayed as a 
percentage of the control with n=3. Significant difference (p<0.05) is indicated by different 
letters, as shown by a and b. 
 
                                                                  
  
 
36
fold (Figure 13b). However, these ligands, both agonist and antagonist, appeared to have 
no effect on expression of GTPCH. There was no significant increase or decrease in 
GTPCH from control levels when treated with both the PPARγ agonist and PPARγ 
antagonist (Figure 14). Thus, PPARγ-induced manipulation of NO production is NF-κB 
dependent, but does not effect tetrahydrobiopterin or GTPCH levels. 
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Figure 14 Effect of PPARγ ligands on GTPCH induction in primary astrocytes. a) GTPCH 
induction in the presence of cDIM1. b) GTPCH induction in the presence of GW 9662. 
Expression was measured by real-time polymerase chain reaction and displayed as a 
percentage of the control with n=3. Significant difference (p<0.05) is indicated by different 
letters, as shown by a. 
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TNFα/IFNγ + + 
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SUMMARY AND CONCLUSIONS 
 Pathogenesis of glial inflammatory processes is a primary cause for parkinsonian 
disorders. Although the exact mechanism for many of these disorders has yet to be 
elucidated, research has indicated that nitric oxide is involved in these pathologies, 
specifically Parkinson’s Disease (PD). Furthermore, it has been shown that several 
compounds including manganese can lead to increased NO production and subsequent 
damage to dopaminergic neurons, the primary cell type lost in PD.  
Recent studies have clarified the mechanism by which Mn accumulation 
increases catalytic conversion of arginine to NO. Accumulation of manganese occurs 
within the inner mitochondrial membrane of glial cells. This buildup over a 24 hour 
period leads to marked increases in NO production by the astrocytes. This enhanced NO 
production stems from manganese-driven disruption of Na+ pumps which in turn causes 
an accumulation of mitochrondrial calcium. The increase of mitochondrial calcium is 
toxic to the organelle and induces formation of reactive oxygen species (ROS), as well 
as decreased mitochondrial function(Liu et al., 2002; Barhoumi et al., 2004). Previously 
published reports show that increased ROS leads to increased NF-κB activation and 
therefore to induction of nos2.  This study confirms reports of a synergistic increase in 
NO production and furthermore reports that this increase is due to transcriptional 
activation of nos2.  
PPARs are ubiquitous compounds with several known capacities, including 
inducing transcription. The sub-type PPARγ is known to exert inhibitory effects on NO 
production. As such, we studied the ability of novel PPARγ effectors to alter the level of 
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manganese and cytokine induced glial NO. Previously these compounds had been used 
to suppress tumor growth, yet their efficacy in interdicting NO production had not yet 
been tested. We found that the PPARγ agonist cDIM1 attenuated NO production in cells 
previously treated with Mn and cytokines in a dose-dependent manner. Conversely, 
treatment of these cells with the PPARγ antagonist GW9662 led to a dose-dependent 
increase of  NO production. Our findings indicate the effects of the agonist are not non-
specific, (i.e. that it does act by pharmacologically manipulating PPARγ rather than by 
some non-specific effect.) They also suggest a baseline level of PPARγ inhibition, even 
under non-treated conditions. 
Increased manganese treatment has been linked to increased activation of Nik, 
and connections between Nik and ROS have been suggested, though no evidence has 
been put forth. Nik is known to phosphorylate both isoforms of IκB Kinase (IKK), 
which in turn leads to the phosphorylation of IκB (the inhibitory sub-unit of NF-κB), its 
subsequent dissociation from the p65/p50 complex, and its ubquitination and 
degradation. The p65/p50 complex is then free from inhibitory signals and can cross the 
nuclear membrane bind to its promoter. It is thought that the signal created by 
mitochondrial accumulation of manganese and the signaling cascade produced by the 
pro-inflammatory cytokines converge upon NF- κB, together causing a greater activation 
and significant increase in NOS levels and NO production (Figure 15).  
 To determine whether or not manganese and cytokine treatment enhances NF-κB 
dependent transcriptional activation, and likely nos2 activation, we examined NF-κB 
EGFP reporter cells from transgenic mice. We found that addition of manganese and 
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cytokines partially activated NF-κB, while addition of the two in concert led to much 
stronger fluorescent activity (Figure 7). This is consistent with the idea that the signals  
are convergent upon NF-κB. Moreover, attenuation of EGFP signal displayed with the 
addition of the PPARγ agonist as well as the augmentation of signal with the addition of 
the PPARγ antagonist are strong indicators that these ligands operate through an NF-κB 
dependent mechanism. Such findings point to the possibility of pharmacological 
intervention as a method of interdicting manganese stimulated nitric oxide and by 
extension contributing to the possible prevention of parkinsonian disorders, most notably 
idiopathic PD (Figure 15). 
This idea of synergistic enhancement provides rationale for studying the effects 
of both Mn and cytokines on endogenous NO production. It also mimics a possible 
clinical condition in which excessive accumulation of Mn causes an increase in the 
baseline level of NO produced. When an inflammatory event activates the cytokine 
pathway, the signal cascade combines with manganese-induced signals to create a 
condition where neuronal destruction occurs due to extended excessive NO exposure. 
Indeed, our study confirmed previous results that show that the combination of 
manganese and cytokines produces greater NO than either substance alone. Furthermore, 
it shows that while this increase is also reflected in increased induction of GTPCH, 
PPARγ influences this NO production solely through an NF-κB mechanism and not 
through the alteration of GTPCH. 
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Figure 15 Exposure to manganese and cytokines causes a synergistic  
enhancement of NF-κB activation and subsequent production of  
     NOS2 and increase in NO levels. This pathway may be inhibited by activation of       
     PPARγ which inhibits NO production through an NF-κB mediated process. 
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